<DOC>
	<DOCNO>NCT03077412</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy filgotinib compare placebo establish combined fistula response Week 24 . Participants option enter separate long-term extension study meet eligibility requirement .</brief_summary>
	<brief_title>Efficacy Safety Filgotinib Treatment Perianal Fistulizing Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Key Males nonpregnant , nonlactating female , age 18 75 year , inclusive base date screen visit Diagnosis Crohn 's disease ( CD ) minimum duration CD least 3 month Has drain perianal fistulae complication CD , confirm MRI screening . Previously demonstrate inadequate clinical response , loss response , intolerance least 1 follow agent ( depend current country treatment recommendations/guidelines ) : Antibiotics Immunomodulators TNFÎ± Antagonist Is willing able undergo MRI per protocol requirement Is willing able undergo flexible sigmoidoscopy per protocol requirement Key Presence current rectovaginal fistula Presence ulcerative colitis ( UC ) , indeterminate colitis , ischemic colitis , fulminant colitis , toxic megacolon History total proctocolectomy , total colectomy , presence ileostomy colostomy , likely requirement surgery study Use prohibit concomitant medication describe study protocol Active tuberculosis ( TB ) history latent TB treat Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>